A cross-sectional study was carried out in 2016 in the research project No 4/2016. We selected 98 patients aged 40-89 and diagnosed with hypertension. The patients were admitted to Cardiology Clinic One of the University Hospital in Pleven. The study aimed to measure and compare direct and indirect costs of hypertensive patients aged 40-89 years, who were treated with lisinopril and perindopril. We estimated the total and average costs of 50 (51.0%) patients treated with lisinopril and 48 (49.0%) treated with perindopril. Males were 46.4%, and the mean age of the sample was 65.9.0±11.2 years. Data were processed by Statistical Package for Social Science version 19.0 (SPSS.v.19.0). Total costs exceeded amount reimbursed for the clinical path (BGN 420.00) in 64.6% of the patients treated with perindopril and 48.0% of the patients treated with lisinopril. We found that treatment costs within 6-months after discharge were BGN 673.82 in patients treated with lisinopril, as compared to BGN 171.92 reimbursed by the National Health Insurance Fund (NHIF), and BGN 781.18 for those treated with perindopril, compared to BGN 216.33 reimbursed by NHIF. The NHIF reimbursement rate for antihypertensive treatment is on access to treatment for arterial hypertension.
Introduction
Hypertension is one of the most common diseases societies and health systems. The economic burden of cost of the antihypertensive treatment, and second, the cost of managing the complications associated with uncontrolled hypertension.
The study aimed to measure and compare direct and indirect costs of hypertensive patients treated with lisinopril and perindopril.
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to November 2016. The study was part of project No 4/2016 "Economic assessment of antihypertensive therapy with lisinopril and perindopril by cost-effectiveness analysis and cost-utility analysis" and was approved by the MU -Pleven. All 98 patients aged 18 or older who met the inclusion criteria participated in the study (Table 1) . They were admitted to the Cardiology Clinic One the University Hospital -Pleven. All the patients were diagnosed with arterial hypertension (AH) in the clinical path (CP) No52 acute and subacute heart failure classes III-IV.
We followed up the patients six months after discharge and interviewed them by phone about drug use, blood pressure and drug-induced fatal and nonfatal cardiovascular diseases as well as costs due to ACE-inhibitor therapy. Some patients were not followed up after discharge because of missing or wrong contact information.
Data
Direct costs included all resources used in the process of the antihypertensive treatment. These were covered by the hospital, National Health Insurance Fund (NHIF) and the patients.
Information about actual hospital costs per treated patient based on CP No 52 was provided by Department of Medical Informatics and Statistics of the University Hospital -Pleven. CP No 52 reimbursement amounted to BGN 420 in 2016 [1] .
We used retail prices of lisinopril and perindopril from the Positive drug list [2] to evaluate outpatient treatment costs (Table 2) . We also included all outpatient drug-induced visits within six months after discharge from the hospital. In cases of fully-insured persons, we used reimbursement price per outpatient visit to a specialist, BGN 19 .00 in 2016 [3] . In other cases, direct payments by the user occurred as out-of-pocket payments (OOPs) for specialist services without a GP referral on a fee-forservice basis by the price-list of the healthcare provider.
User charges to see a doctor (BGN 2.90) and hospital (BGN 5.40 per day of hospital stay up to 10 bed-days per year) were calculated and added to direct costs of the patient [4] . In the calculation of user charges, we took into consideration the reduced charges for retirees (BGN 1). The difference between the full and reduced charge (BGN 1.90) is covered by the Ministry of Health [5] .
Patient time was the time that patient spent while seeking and receiving healthcare services and was calculated as the price of average income for extra working hours [6] . Minimum wage per hour was BGN 2.63 multiplied by 2=BGN 5.26.
Relatives' time for accompanying the patient to and from the hospital was calculated as a minimum salary per hour [6] . Relatives' time was calculated as BGN 2.63 in 2016.
Patients and relatives' travel expenses (by car, bus, train, etc.) to and from the hospital and other health facilities were calculated and added to direct costs. Three of the hypertensive patients were transported to the hospital by ambulance of the Center of Emergency Medical Care. These costs were calculated multiplying the distance travelled by the average fuel consumption (10 l/100 km) [7] and were covered by a transfer from the public budget [8] .
Indirect costs included production losses. Since most of the participants in our study were retirement or illness pensioners, indirect costs were not measured. The average values in the distribution of age and costs are shown by mean and standard deviation (SD) for a symmetrical distribution or median (Mdn) -for an asymmetric distribution. We measured and compared total and average costs of the patients treated with lisinopril and perindopril.
Statistical Analysis

Results
Total Hospital Costs
We found that total hospital costs in all 98 patients treated on CP N0 52 amounted to BGN 41160.00. These costs exceeded the reimbursement price of the clinical pathway (BGN 420.00) in 56.1% of all the cases (in 64.6% of the patients treated with perindopril and in 48.0% of the patients treated with lisinopril, respectively). Increased hospital costs in some patients treated with ACE-inhibitors were most likely due to more severe forms of the disease, requiring further examinations and more prescription drugs. On the other hand, NHIF does not reimburse costs of hospital provider in case of changes in therapy (Table 3) . The interval between minimum and maximum actual costs was higher in the patients treated with perindopril than in the patients treated with lisinopril. The difference between the two patient groups was due to higher direct costs in most patients treated with perindopril.
Outpatient Costs
Total costs of the patients for 6-month drug treatment after discharge with lisinopril were BGN 673.82 and BGN 781.18 -with perindopril. Median out-of-pocket monthly expenses per patient were BGN 5.7 for perindopril, as compared to BGN 4.3 for lisinopril ( Figure 1 ). NHIF reimbursed BGN 216.33 of the costs for treatment with perindopril and BGN 171.92 -with lisinopril for six months after discharge (Table 3) . (Table  3) . Travel expenses for relatives to accompany patients treated with lisinopril to and from health facilities amounted to a total of BGN 277.12. Such expenses associated with patients treated with perindopril were BGN 202. 30 .
Most of the patients in the study were exempt from hospital stay charges because they had chronic diseases included in a list appended to National Framework Contract [3] . Cost sharing in the patients treated with lisinopril per visit to a physician was BGN 5.80. User charges for a visit to the hospital were BGN 135.00 for the patients treated with lisinopril, and BGN 16.20 for the patients treated with perindopril.
The hospital stay of those treated with lisinopril cost more -BGN 416.54 than that of patients treated with perindopril (BGN 394.50).
Relatives' time spent to accompany a patient to and from the hospital cost BGN 65.75 for patients treated with lisinopril, and BGN 65.12 for those treated with perindopril.
Total costs were higher in the patients treated with perindopril (BGN 32 680.88, BGN 
Discussion
Hypertension is among the most prevalent worldwide diseases and a major challenge for individuals, society and health systems for many reasons [10] . Worldwide, the prevalence of hypertension exceeds 40%. Nearly one of every three Bulgarian adults aged 25-64 has a high blood pressure, respectively 42.8% males and 39.7% females. This prevalence increases with age -from 6.6% in age group 25-34 to 58.3% in individuals over 65 years of age [10] . Recent statistics have shown an adverse trend of hypertension among the young population [11, 12] .
Most hypertensive patients have failed to achieve blood pressure levels lower than 140/90 mm Hg [10] [11] [12] [13] [14] . The proportion of well-controlled hypertension among the treated hypertensive patients in Bulgaria was smaller (6-10%), as compared with 27% for other eight countries in Central and Eastern Europe [15] .
Only one-fourth of the patients with hypertension in Bulgaria are on the same drug treatment for a year. More than 35% of the hypertensive patients discontinued medication, treatment costs were reimbursed partially (25- 50%) by NHIF, and reimbursement is higher for combined antihypertensive therapy than for monotherapy. Patient cost sharing for the two antihypertensive drugs was BGN 903.00 in 2014 [17] [18] [19] . Almost one-third of the costs for antihypertensives are related to the discontinuation of the initial drug therapy, and another 20% are due to changes in the treatment [20] .
We found that the average out-of-pocket monthly expenses per patient treated with perindopril were BGN 5.7 and BGN 4.3 for lisinopril. Similar results were reported by T. Vekov (2009) [17] . Monthly costs for ACE inhibitor treatment per patient varied in the range of $10-100 in the USA, but when the patient was included to Medicare using generic drugs, costs decreased to $4 per month [21] [22] . One limitation of drug treatment for hypertension in Bulgaria is the lower number of ACE inhibitors prescriptions to patients and high-dose monotherapy, as compared to the USA and Western European countries [17, 21, 23] . Monotherapy is effective in 25-40% of the hypertensive patients, while and 60-75% need combined antihypertensive therapy [15] .
Monthly costs for drug treatment of hypertension combined with ischemic heart disease per patient were BGN 61.85 and BGN 120.60 -for hypertension combined with heart failure. Patient cost-sharing was almost 75% [17] . In fact, most of the patients included in this study took more medications in addition to ACE-inhibitors, although these costs were not added to patient cost sharing for drug treatment outside the hospital. Thereby, we could calculate precisely the costs related to drug treatment of hypertension, but it was impossible to measure a net effect of drugs on newly diagnosed diseases. Moreover, actual patients' out-of-pocket expenses for complex drug treatment per month in our hypertensive patients would be much higher than the cost sharing for ACE inhibitors. Monthly costs for monotherapy per patient were BGN 10.14 in 2008, BGN 18.64 for a doubledrug combination, and BGN 54.41 -for a tripledrug combination. Similar results were reported by Ivanova and Petrova (2009) [24] . Moreira et al. (2009) [17] [18] [19] . According to that study, the total costs of NHIF for drug treatment on an outpatient with ACE inhibitors for six months were BGN 388.25 (BGN 171.92+216.33).
Direct costs were BGN 7637.47 higher for the patients treated with perindopril than for the patients treated with lisinopril. Hospitalization costs were the primary component of direct costs in that study, although these costs came second in the survey of Krzysztoszek et al. (2014) [27] . Lee et al. (1997) [23] reported that the total drug costs in a hypertension clinic during a sevenweek study period were £21 510, and prices of ACE inhibitors were disproportionately higher and considerably increased the treatment cost. A study by Azarisman et al. (2009) [29] high, especially for perindopril (RM 320 539.53 or 14.5% of total drug costs). However, the full median price per month in elderly hypertensive patients was higher for older ACE inhibitors than newer ones [25] . Hospitalization costs increased with poorer adherence to and persistence with antihypertensive therapy [30, 31] .
Greater compliance with antihypertensive therapy has been shown to be associated with lower costs for physicians. Rizzo et al. (1996) [31] reported that a person with uncontrolled hypertension loses 5.5 workdays per year and that 3.5 of the disability days could be avoided if treatment adherence was optimized. We found that patient time-costs were BGN 416.54 for treatment with lisinopril, as compared to BGN 394.50 for that with perindopril.
All the 44 studied patients treated with perindopril paid BGN 943.66 for travelling expenses, and these costs were the essential component of the direct non-medical costs compared to Krzysztoszek et al. (2014) [27] . Forty-nine of our patients treated with lisinopril paid for travelling expenses less than the 44 patients treated with perindopril.
The total costs for 6-months pharmacotherapy in patients treated with lisinopril was BGN 7283 cheaper than perindopril. Direct non-medical costs per patient were BGN 172.89 lower in lisinopril than perindopril. These results were inconsistent, compared to Heidenreich et al. (2008) [28] who reported higher direct and indirect costs in patients treated with lisinopril.
Many studies have reported cost-saving for society by lowering blood pressure, especially in patients with cardiovascular disease ($1230 per patient in men and $650 in women) or second-stage hypertension ($600 per patient in men) [13] . Annual changes in the treatment costs by clinical guideline implementation for treatment and management for achieving blood pressure target levels could save €1.26 billion for health insurance fund systems [10] .
Conclusions
Total direct treatment costs are lower in patients treated with lisinopril than in patients treated with perindopril.
The NHIF reimbursement level for cover all direct costs. Increased hospital costs and out-of-pocket payments are a barrier to accessing treatment for arterial hypertension.
